5results about How to "Easy to administer" patented technology

The present application relates to a kind of dolasetron mesylate suppositories, it is characterized in that, component includes: dolasetron mesylate, cyclodextrin or its derivative, shell matrix, hardness regulator, gel matrix, water;The gel matrix includes polyacrylic acid derivative grafted chitosan in it.The present application uses polyacrylic acid derivative grafted chitosan and cyclodextrin to prepare dolasetron mesylate liquid gel, significantly improve the stability and bioavailability of suppository;And can achieve the purpose of quick effect and slow release long-acting simultaneously.The suppository of the present application is very convenient for old people, children or patients who cannot be administered orally, and the treatment population of the product belongs to the patient who is inconvenient to swallow.

The application provides a preparation of gramicidin and an antibacterial hydrogel preparation of the gramicidin, and discloses medical uses of the gramicidin, and provides a recombinant gramicidin, heterologous expression of the gramicidin is realized by constructing a Pichia pastoris recombinant strain, and the antibacterial activity of the gramicidin is retained, and the method has the advantages of simplicity and rapidness. Meanwhile, the hydrogel preparation of the gramicidin provided by the application shows good potential for treating wound infection of a diabetic mouse, and has the performance of rapid adhesion and hemostasis, lays a foundation for development of a new antibacterial drug, and provides a new direction for treatment of chronic inflammatory wounds and open bleeding.

This invention provides a circRNA-LNP delivery system for in vivo induction of iTregs, its preparation method, and its applications. The delivery system includes circRNA encoding human TGF-β1, lipid nanoparticles encapsulating the circRNA, and IL-2 modified on the surface of the lipid nanoparticles. This invention synergistically combines retinoic acid as a functional immunomodulatory small molecule with five lipids, significantly improving the uptake efficiency of Treg precursor cells and the induction efficiency of iTregs. It can also efficiently increase the proportion of functional iTregs in diseased tissues in vivo, demonstrating excellent therapeutic effects on immunomodulatory diseases such as ulcerative colitis, and providing a novel technical pathway for the radical treatment of autoimmune and inflammatory diseases.

The present application belongs to the technical field of pharmaceutical chemistry, and particularly relates to a crystal form of lamivudine salt of m-hydroxybenzoic acid and a preparation method thereof. The crystal form has an X-ray diffraction spectrum expressed by 2theta using Cu-Kalpha radiation, and has characteristic peaks at least at 9.26+ / -0.2, 12.56+ / -0.2, 13.05+ / -0.2, 14.59+ / -0.2, 17.45+ / -0.2, 20.30+ / -0.2, 21.76+ / -0.2, 23.37+ / -0.2, 25.05+ / -0.2 and 27.58+ / -0.2; the crystal form is composed of a molecule of lamivudine, a molecule of m-hydroxybenzoic acid and a molecule of n-butanol as a basic unit; meanwhile, the crystal form has good solubility, provides ideal raw material for preparing parenteral dosage forms which are convenient to administer and have rapid effect, and thus better meets the requirements of clinical application.

The application discloses a small-molecule inhibitor targeting NID1 and application, and relates to the technical field of biological medicines.The application selects W-5 hydrochloride as a small molecule for specifically inhibiting the function and activity of NID1 by molecular docking prediction and function verification from existing small-molecule drugs, and finds and verifies for the first time that W-5 can directly combine and inhibit NID1 protein.Starting from the core pathological link of "NID1-CSCs-resistance / metastasis", it is verified through experiments that W-5 hydrochloride can effectively combine with NID1, and can inhibit lung adenocarcinoma cell stemness, invasion and drug resistance by inhibiting the function of NID1 in lung adenocarcinoma.The application not only provides a clear orientation and a solid foundation for chemical optimization, structure modification, dosage form development and pharmacokinetics / toxicology (ADMET) research of a clear mechanism of directly targeting NID1, but also discovers new medicinal value of W-5 hydrochloride.